Quarterly report pursuant to Section 13 or 15(d)

6. INVENTORIES

v3.8.0.1
6. INVENTORIES
3 Months Ended
Mar. 31, 2018
Inventories Abstract  
6. INVENTORIES

The following table provides the components of inventories:

 

   

March 31,

2018

December 31,

2017

         
Raw materials   $ 8,962,207     $ 10,395,433  
Work-in-progress     1,265,586       1,265,339  
Finished goods     2,211,009       967,409  
Total inventories   $ 12,438,802     $ 12,628,181  

   

Inventories are stated at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. Finished goods inventories as of March 31, 2018 is comprised of Nabi-HB, a portion of which is recorded at fair value as part of the purchase price allocation of the Biotest Assets acquired. Raw materials includes materials expected to be used in the production of Nabi-HB, Bivigam and RI-002. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred.